In September 2009, Axial Biotech announced the commercial launch of the ScoliScore AIS Prognostic Test.
2.
Based on this discovery, he developed a highly sophisticated and accurate prognostic test for widespread clinical use.
3.
"' DecisionDx-UM "'is a prognostic test that accurately determines the metastatic risk associated with ocular melanoma tumors of the eye.
4.
In addition to DecisionDx-UM, Castle offers prognostic tests for glioblastoma multiforme ( DecisionDx-GBM ) and low-grade glioma ( DecisionDx-LGG ).
5.
The genetic research behind the clinically validated ScoliScore AIS Prognostic Test began in 2003, as researchers explored the entire human genome searching for genes that were linked to Scoliosis.
6.
Castle s mission is to serve individuals afflicted with rare cancers by offering accurate prognostic tests which provide information for making critical decisions regarding an individual s surveillance and treatment regimens.
7.
The lack of accurate prognostic tests to identify which patients are at risk of developing clinically overt metastatic disease has been a significant issue in the management of individual patients with uveal melanoma.
8.
Elevated levels of suPAR are associated with increased risk of systemic inflammatory response syndrome ( SIRS ), cancer, Focal segmental glomerulosclerosis, cardiovascular disease, type 2 diabetes, infectious diseases, HIV, and mortality . suPARnostic is a prognostic test used to detect suPAR levels in blood plasma.
9.
Although suPARnostic currently does not have FDA approval, it is CE / IVD marked for distribution throughout Europe . suPAR is a prognostic test to indicate general health, and it cannot be used as a diagnostic tool to suggest a particular illness . suPAR cannot be used in the detection of brain tumors because the suPAR molecule cannot migrate through the blood brain barrier.
मोबाइल